Catalent (CTLT) Receives Daily Coverage Optimism Score of 0.14

Press coverage about Catalent (NYSE:CTLT) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalent earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.2739857744363 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

Shares of Catalent (NYSE:CTLT) traded down $0.33 during trading hours on Friday, hitting $41.08. 513,227 shares of the stock were exchanged, compared to its average volume of 805,173. The stock has a market capitalization of $5,501.71, a price-to-earnings ratio of 47.22, a PEG ratio of 2.66 and a beta of 1.41. Catalent has a fifty-two week low of $25.51 and a fifty-two week high of $43.39. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. Catalent’s revenue was up 23.0% compared to the same quarter last year. During the same period last year, the company posted $0.16 earnings per share. sell-side analysts expect that Catalent will post 1.46 EPS for the current fiscal year.

Several analysts have weighed in on the company. BidaskClub cut Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, September 7th. Morgan Stanley raised shares of Catalent from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $29.00 to $48.00 in a report on Thursday, September 21st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $44.44.

In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average price of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.

WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.

Leave a Reply